{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/stroke-tia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3fa3210c-0be8-5167-adb3-6c05aaef00bc","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 7a7b9027-2944-4a3a-9a05-1121357d6a95 --><h2>Changes</h2><!-- end field 7a7b9027-2944-4a3a-9a05-1121357d6a95 -->","summary":null,"htmlStringContent":"<!-- begin item aceb28c2-2e40-49ac-9d4b-2537fecaf95e --><!-- begin field 3a7b05f4-192c-4af8-96b9-ec3095fad691 --><p><strong>August 2020 </strong>— minor update. New NICE quality standard QS194 added.</p><p><strong>January to March 2017 </strong>— reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone some restructuring. The recommendation on risk stratification of people with suspected TIA has changed - all people presenting with suspected TIA within the last week should be referred urgently (to be seen within 24 hours) to a stroke physician without risk stratification.</p><!-- end field 3a7b05f4-192c-4af8-96b9-ec3095fad691 --><!-- end item aceb28c2-2e40-49ac-9d4b-2537fecaf95e -->","topic":{"id":"f543bb01-4edc-57a6-ba31-aaa6b6b6e6e8","topicId":"63954e32-591d-4f33-bcbb-3fdecfc69796","topicName":"Stroke and TIA","slug":"stroke-tia","lastRevised":"Last revised in August 2020","chapters":[{"id":"3690cd7d-0a6b-548a-a527-b276c3924bab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aef0c419-4ee2-52b6-b781-c8afa9a11104","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8baebfc-07d7-5c4a-8d95-4d2bf1f42c38","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3fa3210c-0be8-5167-adb3-6c05aaef00bc","slug":"changes","fullItemName":"Changes"},{"id":"e606f403-4b76-5e30-a38d-6aa4b6e3b4b1","slug":"update","fullItemName":"Update"}]},{"id":"fe337d01-2447-58d3-93e8-a6b09a4920d4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"08277b76-a6c4-566a-a594-131c32067735","slug":"goals","fullItemName":"Goals"},{"id":"acf4fa85-325c-5018-8bc2-9d877522bf6f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"18bc44dc-3e6b-58ae-9d3c-abca76b13c16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4eb59f42-29b3-56e1-993f-1ce8ab7b2969","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"08107877-662b-59e6-a30a-b21e19250f23","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ff061807-ab05-5af8-8dd4-01db71526d0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a0b319c1-8df3-5206-93ce-302f6b981e82","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a0bcd779-defb-50a7-86f6-ab4b2c701ac7","slug":"definition","fullItemName":"Definition"},{"id":"c40d717d-0b67-5cb2-b86c-c67045400115","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"d1569ff2-5da1-51a0-9720-75ad88c0ad86","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ee8fc150-6899-5c75-a0d0-6241055dfd09","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d5730239-5d67-598b-b9d1-f339079de3eb","slug":"complications","fullItemName":"Complications"},{"id":"9b730ca3-d3ee-552b-8145-f6eadf244a63","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"caea5ae7-0be8-5c7c-8bef-7162c7171e9d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"67902a93-a36b-58c6-a67a-3eb89654460c","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2bc808d1-f905-575d-90b2-8481eb492905","slug":"assessment","fullItemName":"Assessment"},{"id":"6562a8bf-1396-58ba-b1b9-a1914e4adebe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"2d634696-3361-5fd3-b676-609f3c31c2f1","fullItemName":"Management","slug":"management","subChapters":[{"id":"1baf2362-0da4-599f-8f9a-12d0124253a0","slug":"suspected-acute-stroke","fullItemName":"Scenario: Suspected acute stroke"},{"id":"15af1682-8287-57f9-90f1-954c1f71792e","slug":"suspected-transient-ischaemic-attack","fullItemName":"Scenario: Suspected transient ischaemic attack"},{"id":"91d820f4-4249-556c-99e2-4ac86d3ebd2a","slug":"secondary-prevention-following-stroke-tia","fullItemName":"Scenario: Secondary prevention following stroke and TIA"},{"id":"84ca3884-d693-5209-b048-6ff53b4ae2be","slug":"management-of-long-term-complications-of-stroke","fullItemName":"Scenario: Management of long term complications of stroke"}]},{"id":"30a83b67-7804-5b41-a647-98d32dce018a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ebfe1dbe-0d9c-5a26-82b4-4d0a308a19ac","slug":"antiplatelet-treatment","fullItemName":"Antiplatelet treatment"}]},{"id":"279444c7-61df-5f92-b512-c703ae6cb9fb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8ef8b6ac-1d47-5038-b4d7-4d77faf1a823","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"72590587-c86f-5da1-b397-b7e6cc757702","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7ba85ca6-985e-5af5-b223-0c27f7066797","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b322154e-a2d3-59d1-a7b2-d70b4e7812da","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"18f7eefe-52bd-5ad8-a39c-b96d270599ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8fed8545-5194-53a4-b547-2d6a402857f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"216e65b7-f638-5b35-ad86-30270fbea649","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f8baebfc-07d7-5c4a-8d95-4d2bf1f42c38","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"dd285b9b-58f1-541c-a8e2-a789393b9149","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e57975f2-54fc-45d8-b908-88c9a572b4e6 --><h3>Previous changes</h3><!-- end field e57975f2-54fc-45d8-b908-88c9a572b4e6 -->","summary":null,"htmlStringContent":"<!-- begin item acb76347-fc5e-4f5b-be3e-abdde3ea3a2d --><!-- begin field 67733a32-d702-4789-866b-c7996e84172a --><p><strong>December 2013</strong> — reviewed. A literature search was conducted in September 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. The structure of the topic was changed to improve clarity. Clopidogrel is preferred as the antiplatelet of choice for people who have had a transient ischaemic attack.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2011 </strong>— minor update. The new recommendations on alcohol consumption advising at least 2 alcohol-free days per week, based on guidelines from the House of Commons Science and Technology Committee, have been added. Issued in March 2012.</p><p><strong>January 2012 </strong>— minor update. Amendment to referral information for a transient ischaemic attack, in line with the Quality and outcomes framework guidance for GMS contract 2011/12. Issued in February 2012.</p><p><strong>January 2012 </strong>— minor update. Information from the manufacturer's Summary of Product Characteristics about the possible interaction between pantoprazole and warfarin has been added to drug interactions. Information from the British National Formulary about the potentially serious interaction between proton pump inhibitors and protease inhibitors (atazanavir and saquinavir) has also been added. Issued in January 2012.</p><p><strong>September 2011 </strong>— minor update. Text added to include recommendations from the Scottish Intercollegiate Guidelines Network national clinical guideline 119 <em>Management of patients with stroke: identification and management of dysphagia</em> and national clinical guideline 118 <em>Management of patients with stroke: Rehabilitation, prevention and management of complications, and discharge planning</em>. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>April 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>February 2011 </strong>— updated. The new recommendations from NICE technology appraisal 210 <em>Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events </em>have been incorporated into this topic. Issued in February 2011.</p><p><strong>July 2010 </strong>— minor update. Text added to include NICE Quality Standards relating to Stroke. Issued in August 2010.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>April 2009 </strong>— updated to include the indicators related to stroke and transient ischaemic attack in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract in the <em>Goals and outcome measures </em>section. Issued in May 2009.</p><p><strong>September 2008 to February 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base on primary care treatments has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The title has been changed from <em>TIA — not in atrial fibrillation </em>to <em>Stroke and TIA</em>, to reflect a wider scope, which now includes the primary care management of stroke. Changes to the sections on transient ischaemic attack (TIA) reflect new guidance from the National Institute for Health and Care Excellence (NICE) on using the FAST screening tool when diagnosing TIA, and on standards for referral for specialist assessment.</p><p><strong>October 2008 </strong>— minor typographical correction to an in-text citation. Issued in November 2008.</p><p><strong>July 2006 </strong>— minor update to text. Details of the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) study included in <em>Supporting evidence </em>to further support recommendations. Issued in July 2006.</p><p><strong>July to September 2005 </strong>— reviewed. Validated in December 2005 and issued in February 2006.</p><p><strong>July 2005 </strong>— minor update to text to clarify dipyridamole formulations. Issued in July 2005.</p><p><strong>October 2003 </strong>— minor revision. Inclusion of modified-release dipyridamole in the scenario for people intolerant of aspirin. Validated in December 2003, and issued in February 2004.</p><p><strong>June 2003 </strong>— minor update. New advice from the British Heart Foundation on low-dose aspirin and ibuprofen added.</p><p><strong>January 2002 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>December 1998 </strong>— rewritten, replacing previous guidance called <em>Transient cerebral ischaemia</em>.</p><!-- end field 67733a32-d702-4789-866b-c7996e84172a --><!-- end item acb76347-fc5e-4f5b-be3e-abdde3ea3a2d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}